Some Effects of Clofibrate in Hypothyroidism and on the Metabolism of Thyroxine

Mt, Harrison; Rm, Harden

doi:10.1177/003693306601100605

Cited by 14 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vitro studies with clofibrate have shown an increase in TBG binding capacity for thyroxine. 8 This work was supported by McKerron and associates,!o who reported increased TBG binding capacity in 11 of 12 patients treated with clofibrate for one month. In contrast, no consistent effect on binding capacities of TBG or thyroxine-binding prealbumin (TBP A) was observed by Musa, Ogilvie and Dowling.…”

Section: D'iscussionmentioning

confidence: 60%

The effects of MK‐185 on thyroid function

Ryan

Jain

Maha

et al. 1971

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

significant reduction in serum protein-bound iodine and an increase in triiodothyroxine resin uptake in 11 patients with types III and IV hyperlipoproteinemia. The drug was administered orally at dosages of 10, 15, and 20 mg. per kilogram per day each for a period of 4 weeks, respectively. There were 4 week pre-and posttreatment periods with placebo. The free thyroxine levels and 131 124 hour thyroidal uptake before and after MK-185 therapy did not show significant change. Although thyroid-binding globulin capacity was reduced, the change was not significant. It is proposed that the drug interferes with the binding of thyroxine by plasma proteins.

show abstract

Section: D'iscussionmentioning

confidence: 60%

The effects of MK‐185 on thyroid function

Ryan

Jain

Maha

et al. 1971

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

show abstract

“…These changes are identical with those observed when thyroxine alone is administered. Studies by Harrison & Harden (1966) in hypercholesterolaemic patients with severe myxoedema showed that the serum cholesterol was unaffected by clofibrate until a small supplement of thyroxine is added. The hypolipidaemic effect of thyroxine treatment is significantly enhanced by the simultaneous administration of clofibrate.…”

Section: Clofibrate*mentioning

confidence: 99%

Experimental approaches to the prophylaxis and treatment of ischaemic heart disease

Fitzgerald¹

1971

Postgraduate Medical Journal

View full text Add to dashboard Cite

show abstract

“…This latter enzyme is specifically increased by thyroxine administration (12). Furthermore the hypolipidemic effect of clofibrate is reduced or abolished in thyroidectomized animals (13), and the thyroxine binding capacity of thyroxine binding globulin is increased by clofibrate administration in man (14,15). Although these metabolic alterations have been clearly demonstrated, they are not correlated with lowering of serum trigiyceride levels, and no changes in serum free thyroxine levels have been noted (15).…”

Section: Introductionmentioning

confidence: 99%

A review of studies on the mode of action of clofibrate and betabenzalbutyrate

Fallon

Adams

Lamb

1972

Lipids

View full text Add to dashboard Cite

Clofibrate and betabenzalbutyrate produce a variety of metabolic alterations in vivo. These include reduction in serum triglyceride and alterations in adipose tissue uptake and release of lipids. Clofibrate displaces thyroxine from albumin binding sites and produces an enlargement of liver and changes in ultrastructure. The biochemical changes produced by clofibrate include reduction in adenyl cyclase activity, inhibition of acetyl CoA carboxylase, inhibition of cholesterol biosynthesis and inhibition of triglyceride formation. Recent studies in this laboratory have shown that the inhibition of hepatic triglyceride formation is an early metabolic consequence of clofibrate administration and precedes the fall in serum triglyceride and several of the other biochemical alterations. Moreover clofibrate and betabenzalbutyrate inhibit the esterification ofsn‐glycerol‐3‐P by rat liver homogenate and microsomal preparations. The initial step in this pathway, acyl‐CoA‐sn‐glycerol‐3‐P acyltransferase, is inhibited by both drugs, in vitro. It is possible that this in vitro inhibition explains the early hypotriglyceridemic effect of these agents.

show abstract

Some Effects of Clofibrate in Hypothyroidism and on the Metabolism of Thyroxine

Cited by 14 publications

References 7 publications

The effects of MK‐185 on thyroid function

The effects of MK‐185 on thyroid function

Experimental approaches to the prophylaxis and treatment of ischaemic heart disease

A review of studies on the mode of action of clofibrate and betabenzalbutyrate

Contact Info

Product

Resources

About